- Home
- CJET vs ABVC Comparison
CJET vs ABVC Comparison
Compare CJET & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- ABVC
- Stock Information
- Founded
- CJET 2009
- ABVC 2015
- Country
- CJET China
- ABVC United States
- Employees
- CJET N/A
- ABVC N/A
- Industry
- CJET Auto Manufacturing
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- CJET Consumer Discretionary
- ABVC Health Care
- Exchange
- CJET Nasdaq
- ABVC Nasdaq
- Market Cap
- CJET 14.3M
- ABVC 12.8M
- IPO Year
- CJET N/A
- ABVC N/A
- Fundamental
- Price
- CJET $1.76
- ABVC $0.54
- Analyst Decision
- CJET
- ABVC
- Analyst Count
- CJET 0
- ABVC 0
- Target Price
- CJET N/A
- ABVC N/A
- AVG Volume (30 Days)
- CJET 69.5K
- ABVC 150.8K
- Earning Date
- CJET 01-28-2025
- ABVC 03-12-2025
- Dividend Yield
- CJET N/A
- ABVC N/A
- EPS Growth
- CJET N/A
- ABVC N/A
- EPS
- CJET N/A
- ABVC N/A
- Revenue
- CJET $10,275,000.00
- ABVC $509,788.00
- Revenue This Year
- CJET N/A
- ABVC N/A
- Revenue Next Year
- CJET N/A
- ABVC N/A
- P/E Ratio
- CJET N/A
- ABVC N/A
- Revenue Growth
- CJET 31.31
- ABVC N/A
- 52 Week Low
- CJET $1.65
- ABVC $0.41
- 52 Week High
- CJET $23.94
- ABVC $1.73
- Technical
- Relative Strength Index (RSI)
- CJET 37.95
- ABVC 47.67
- Support Level
- CJET $1.93
- ABVC $0.50
- Resistance Level
- CJET $2.08
- ABVC $0.58
- Average True Range (ATR)
- CJET 0.17
- ABVC 0.06
- MACD
- CJET -0.06
- ABVC -0.01
- Stochastic Oscillator
- CJET 10.71
- ABVC 20.63
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.